In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis Faith Borgan, Heikki Laurikainen, Mattia Veronese, Tiago Reis Marques, Merja Haaparanta-Solin, Olof Solin, Tarik Dahoun, Maria Rogdaki, Raimo KR Salokangas, Max Karukivi, Marta Di Forti, Federico Turkheimer, Jarmo Hietala, Oliver Howes for the METSY Group JAMA Psychiatry, 2019. doi : 10.1001/jamapsychiatry.2019.1427 IMPORTANCE Experimental and epidemiological studies implicate the cannabinoid 1 receptor (CB1R) in the pathophysiology of psychosis. However, whether CB1R levels are altered in the early stages of psychosis and whether they are linked to cognitive function or symptom severity remain unknown. OBJECTIVE To investigate CB1R availability in first-episode psychosis (FEP) without the [...]
Lire la suiteThe Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis Britta Hahn Schizophrenia Bulletin, 2018, vol. 44, no. 1, 46–53 doi:10.1093/schbul/sbx105 A major factor associated with poor prognostic outcome after a first psychotic break is cannabis misuse, which is prevalent in schizophrenia and particularly common in individuals with recent-onset psychosis. Behavioral interventions aimed at reducing cannabis use have been unsuccessful in this population. Cannabidiol (CBD) is a phytocannabinoid found in cannabis, although at low concentrations in modern-day strains. CBD has a broad pharmacological profile, but contrary to Δ9-tetrahydrocannabinol (THC), CBD does not activate CB1 or CB2 receptors and has at most subtle subjective [...]
Lire la suiteCannabis use, pain and prescription opioid use in people living with chronic non-cancer pain : Findings from a four-year prospective cohort Gabrielle Campbell, Wayne D. Hall, Amy Peacock, Nicholas Lintzeris, Raimondo Bruno, Briony Larance, Suzanne Nielsen, Milton Cohen, Gary Chan, Richard P. Mattick, Fiona Blyth, Marian Shanahan, Timothy Dobbins, Michael Farrell, Louisa Degenhardt Lancet Public Health, 2018, 3, (7): e341–e350. doi:10.1016/S2468-2667(18)30110-5. Abstract Background : There has been growing interest in the use of cannabis and cannabinoids to treat chronic non-cancer pain (CNCP). Cannabis and cannabinoids have attracted attention because of their greater safety compared with opioids, and the possibility that their use can reduce opioid [...]
Lire la suiteThe Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients : Pilot Study Gil Bar-Sela, Daniela Zalman, Valerya Semenysty and Eyal Ballan Integrative Cancer Therapies, 2019, Volume 18, 1–8 DOI: 10.1177/1534735419881498 Abstract Background : Cancer-related cachexia and anorexia syndrome (CACS) is a common phenomenon in cancer patients. Cannabis has been suggested to stimulate appetite but research on this issue has yielded mixed results. The current study aimed to evaluate the effect of dosage-controlled cannabis capsules on CACS in advanced cancer patients. Methods : The cannabis capsules used in this study contained two fractions of oil-based compounds. The planned treatment was [...]
Lire la suiteCannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1–2 Phosphorylation Roger Hudson, Justine Renard, Christopher Norris, Walter J. Rushlow and Steven R. Laviolette Journal of Neuroscience, 2019, 39, (44), 8762-8777 Doi : https://doi.org/10.1523/JNEUROSCI.0708-19.2019 Abstract Evidence suggests that the phytocannabinoids Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) differentially regulate salience attribution and psychiatric risk. The ventral hippocampus (vHipp) relays emotional salience via control of dopamine (DA) neuronal activity states, which are dysregulated in psychosis and schizophrenia. Using in vivo electrophysiology in male Sprague Dawley rats, we demonstrate that intra-vHipp THC strongly increases ventral tegmental area (VTA) DA neuronal frequency [...]
Lire la suiteLabeling Accuracy of Cannabidiol Extracts Sold Online Marcel O. Bonn-Miller, Mallory J.E. Loflin, Brian F. Thomas, Jahan P. Marcu, Travis Hyke, Ryan Vandrey JAMA, 2017, Nov 7, 318, (17), 1708–1709. doi: 10.1001/jama.2017.11909 This study compares ingredients listed on the labels of cannabidiol products sold online to actual product constituents determined by laboratory analysis. There is growing consumer demand for cannabidiol (CBD), a constituent of the cannabis plant, due to its purported medicinal benefits for myriad health conditions. Viscous plant-derived extracts, suspended in oil, alcohol (tincture), or vaporization liquid, represent most of the retail market for CBD. Discrepancies between federal and state cannabis laws have resulted in [...]
Lire la suiteTrends in Internet Searches for Cannabidiol (CBD) in the United States Eric C. Leas, Alicia L. Nobles, PhD, Theodore L. Caputi, Mark Dredze, DaveyM. Smith, JohnW. Ayers JAMA Network Open, 2019, 2, (10), e1913853. doi: 10.1001/jamanetworkopen.2019.13853 Introduction Cannabidiol (CBD) is widely promoted as a panacea. For example, the cannabis brand MedMen claims CBD treats acne, anxiety, opioid addiction, pain, and menstrual problems.1 However, the US Food and Drug Administration has only approved highly purified CBD (Epidiolex) for treating epilepsy. To our knowledge, there is currently no population-focused surveillance of public interest in CBD. Consequently, many question whether CBD should be prioritized by public health leaders [...]
Lire la suiteUne université de Houston teste la psilocybine pour la dépression résistante aux traitements - www.NEWSWEED.fr 22 octobre 2019 Aurélien BERNARD Dans la foulée de sa décriminalisation dans quelques villes des États-Unis (Oakland et Denver notamment), la psilocybine intéresse actuellement la communauté scientifique à la recherche de preuves d’efficacité thérapeutique. Des chercheurs du Science Health Center de l’Université du Texas à Houston (UTHealth) ont annoncé qu’ils étudiaient la psilocybine pour la dépression réfractaire aux traitements. PUBLICITE L’étude est inspirée par des recherches scientifiques antérieures qui suggèrent que la psilocybine agit pour créer de nouveaux circuits mentaux. Une étude de 2012 a conclu que la substance pouvait permettre [...]
Lire la suiteAssessment of the Psychotherapeutic Effects of Ritual Ayahuasca Use on Drug Dependency : A Pilot Study Xavier Fernández, Rafael Guimarães dos Santos, Marta Cutchet, Sabela Fondevila, Débora González, Miguel Ángel Alcázar, Jordi Riba, José Carlos Bouso, Josep María Fábregas, Xavier Fernández, Rafael Guimarães dos Santos in "The Therapeutic Use of Ayahuasca", Chapter 11, 183-196 Beatriz Caiuby LABATE, Clancy CAVNAR Editors, Springer-Verlag, Berlin, Heidelberg, 2014 First Online: 23 November 2013 Abstract Using personality, psychopathology, and neuropsychological assessment instruments, our team assessed the therapeutic effects of an ayahuasca ritual treatment. Data was collected at the Institute of Applied Amazonian Ethnopsychology (IDEAA), in the Brazilian Amazon Basin. Psychological assessments [...]
Lire la suiteEMA Panel Backs Esketamine Nasal Spray for Resistant Depression Megan Brooks Medscape Medical News, October 18, 2019 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of esketamine nasal spray (Spravato, Janssen-Cilag) in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) for adults with treatment-resistant major depressive disorder (TRD). Patients are considered to have TRD if they have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode. Spravato will be available as a 28 mg nasal spray solution. The safety and [...]
Lire la suite